The device uses vibrating motors, similar to those found in mobile phones, to distract the brain into focusing on something other than trying to control the patient's limbs.
The study has shown correlation between pulse rate and identification of a woman's fertile window; the company also announced new updates for its mobile app.
The study aims to help validate whether advanced personal fitness trackers can be used to help bring precision-based health solutions to consumers.
The device uses two hundred small tactile biosensors that map the surface of the breast and monitor changes in texture, color and temperature.
The company reported Q1 revenues of $299 million with U.S. accounting for 52% of the figure.
The device is designed for chronically ill patients, providing individualized analytics to improve patient outcomes and reduce hospitalization.
The experiential technology can recreate disease symptoms to put physicians and caregivers in patients' shoes.
Compared to currently available wearables, Verily's device offers scalable collection of complex datasets across clinical and observational studies.
The device is waterproof and includes such high-end fitness monitoring tools as VO2 max and fitness age, along with wellness monitoring with all-day stress tracking.
Worldwide wearable device shipments will grow from 102.4 million in 2016 to 237.5 million in 2021, representing a five-year CAGR of 18.3%.